JP2017514787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514787A5 JP2017514787A5 JP2016553489A JP2016553489A JP2017514787A5 JP 2017514787 A5 JP2017514787 A5 JP 2017514787A5 JP 2016553489 A JP2016553489 A JP 2016553489A JP 2016553489 A JP2016553489 A JP 2016553489A JP 2017514787 A5 JP2017514787 A5 JP 2017514787A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- april
- composition
- variant
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000021161 Plasma cell disease Diseases 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 208000007452 Plasmacytoma Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 102000001493 Cyclophilins Human genes 0.000 claims description 2
- 108010068682 Cyclophilins Proteins 0.000 claims description 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 12
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 239000004333 gold (food color) Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403479A GB201403479D0 (en) | 2014-02-27 | 2014-02-27 | Molecule |
| GB1403479.7 | 2014-02-27 | ||
| GB201403481A GB201403481D0 (en) | 2014-02-27 | 2014-02-27 | Chimeric antigen receptor |
| GB1403481.3 | 2014-02-27 | ||
| GB1409759.6 | 2014-06-02 | ||
| GB201409759A GB201409759D0 (en) | 2014-06-02 | 2014-06-02 | Molecule |
| GB201409761A GB201409761D0 (en) | 2014-06-02 | 2014-06-02 | Chimeric antigen receptor |
| GB1409761.2 | 2014-06-02 | ||
| PCT/GB2015/050557 WO2015128653A2 (en) | 2014-02-27 | 2015-02-26 | Ligand |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107701A Division JP6707496B2 (ja) | 2014-02-27 | 2017-05-31 | Ａｐｒｉｌバリアント |
| JP2019014039A Division JP2019068855A (ja) | 2014-02-27 | 2019-01-30 | Ａｐｒｉｌバリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514787A JP2017514787A (ja) | 2017-06-08 |
| JP2017514787A5 true JP2017514787A5 (enExample) | 2018-02-15 |
| JP6556156B2 JP6556156B2 (ja) | 2019-08-07 |
Family
ID=52633311
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553489A Expired - Fee Related JP6556156B2 (ja) | 2014-02-27 | 2015-02-26 | Ａｐｒｉｌバリアント |
| JP2017107701A Expired - Fee Related JP6707496B2 (ja) | 2014-02-27 | 2017-05-31 | Ａｐｒｉｌバリアント |
| JP2019014039A Pending JP2019068855A (ja) | 2014-02-27 | 2019-01-30 | Ａｐｒｉｌバリアント |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107701A Expired - Fee Related JP6707496B2 (ja) | 2014-02-27 | 2017-05-31 | Ａｐｒｉｌバリアント |
| JP2019014039A Pending JP2019068855A (ja) | 2014-02-27 | 2019-01-30 | Ａｐｒｉｌバリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10752665B2 (enExample) |
| EP (2) | EP3243831A1 (enExample) |
| JP (3) | JP6556156B2 (enExample) |
| CN (1) | CN106414502A (enExample) |
| AU (1) | AU2015221933B2 (enExample) |
| CA (1) | CA2939411A1 (enExample) |
| ES (1) | ES2737690T3 (enExample) |
| WO (1) | WO2015128653A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015128653A2 (en) | 2014-02-27 | 2015-09-03 | Ucl Business Plc | Ligand |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| US11384350B2 (en) | 2014-12-15 | 2022-07-12 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing |
| JP6921001B2 (ja) | 2015-04-13 | 2021-08-18 | ファイザー・インク | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
| SG10202012157QA (en) | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| KR20190057308A (ko) | 2016-09-02 | 2019-05-28 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물 |
| WO2018121679A1 (zh) * | 2016-12-30 | 2018-07-05 | 四川大学 | 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途 |
| AU2018226857B2 (en) | 2017-03-03 | 2025-01-02 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| KR20250010043A (ko) * | 2017-10-18 | 2025-01-20 | 프레시전 인코포레이티드 | 스페이서를 포함하는 폴리펩타이드 조성물 |
| KR20200079511A (ko) | 2017-11-01 | 2020-07-03 | 허밍버드 바이오사이언스 홀딩스 피티이. 엘티디. | Cd47 항원-결합 분자 |
| GB201720426D0 (en) * | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
| US20210054086A1 (en) * | 2018-01-10 | 2021-02-25 | The General Hospital Corporation | Immune cells expressing a chimeric antigen receptor |
| US20200054675A1 (en) | 2018-06-01 | 2020-02-20 | Washington University | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
| CA3103610A1 (en) * | 2018-06-12 | 2019-12-19 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
| WO2020247618A1 (en) * | 2019-06-04 | 2020-12-10 | The General Hospital Corporation | Antibodies and chimeric antigen receptors that target taci |
| CN110642953B (zh) * | 2019-10-12 | 2021-09-17 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向bcma的t细胞受体融合蛋白和应用 |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| KR20240073006A (ko) | 2021-08-11 | 2024-05-24 | 사나 바이오테크놀로지, 인크. | 동종이계 세포 요법을 위한 유전자 변형된 1차 세포 |
| AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| AU2023220128A1 (en) | 2022-02-17 | 2024-08-22 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2024097311A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Hypoimmunogenic mail cells, methods of making and methods of using same |
| WO2025043172A1 (en) | 2023-08-23 | 2025-02-27 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
| WO2025209465A1 (zh) * | 2024-04-02 | 2025-10-09 | 福佑泰生物制药公司 | Taci/bcma嵌合体融合蛋白及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| JP5062606B2 (ja) | 2000-02-16 | 2012-10-31 | ジェネンテック， インコーポレイテッド | Ｔｎｆ関連分子の活性を調節するためのアゴニスト及びアンタゴニストの使用 |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| AU2003268230A1 (en) | 2002-08-30 | 2004-03-19 | Incyte Corporation | Immune response associated proteins |
| WO2004089982A2 (en) | 2003-01-06 | 2004-10-21 | Xencor | April variants and methods thereof |
| US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US20050003480A1 (en) * | 2003-01-06 | 2005-01-06 | Xencor | April variants and methods thereof |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US8003335B2 (en) | 2008-04-30 | 2011-08-23 | Universite Paris-SUD11 | Levels of APRIL in serum and use in diagnostic methods |
| SG194176A1 (en) | 2011-05-27 | 2013-12-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EA201990959A1 (ru) | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| WO2015128653A2 (en) | 2014-02-27 | 2015-09-03 | Ucl Business Plc | Ligand |
| CN110114371A (zh) | 2016-11-11 | 2019-08-09 | 奥托路斯有限公司 | 嵌合抗原受体 |
-
2015
- 2015-02-26 WO PCT/GB2015/050557 patent/WO2015128653A2/en not_active Ceased
- 2015-02-26 EP EP17172770.4A patent/EP3243831A1/en not_active Withdrawn
- 2015-02-26 EP EP15708871.7A patent/EP3110838B1/en active Active
- 2015-02-26 CA CA2939411A patent/CA2939411A1/en not_active Abandoned
- 2015-02-26 JP JP2016553489A patent/JP6556156B2/ja not_active Expired - Fee Related
- 2015-02-26 CN CN201580010156.0A patent/CN106414502A/zh active Pending
- 2015-02-26 US US15/121,644 patent/US10752665B2/en not_active Expired - Fee Related
- 2015-02-26 AU AU2015221933A patent/AU2015221933B2/en not_active Ceased
- 2015-02-26 ES ES15708871T patent/ES2737690T3/es active Active
-
2017
- 2017-05-26 US US15/606,660 patent/US10611811B2/en not_active Expired - Fee Related
- 2017-05-31 JP JP2017107701A patent/JP6707496B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-30 JP JP2019014039A patent/JP2019068855A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514787A5 (enExample) | ||
| Ramos et al. | In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas | |
| US20230081443A1 (en) | Anti-il1rap antibodies | |
| JP2016538830A5 (enExample) | ||
| JP2025032089A (ja) | 腫瘍微小環境を標的とするキメラ抗原受容体 | |
| EP3649150B1 (en) | Ror1 car t-cells | |
| Morsink et al. | Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia | |
| CA2951885C (en) | Use of vista agonists and antagonists to suppress or enhance humoral immunity | |
| Cook et al. | Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions | |
| JP2024096688A (ja) | Ｂａｆｆ－ｒ抗体及びその使用 | |
| JP2018508215A5 (enExample) | ||
| JP2017508466A5 (enExample) | ||
| Low et al. | Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen | |
| JP2016537966A5 (enExample) | ||
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| JP2020500542A5 (enExample) | ||
| Larson et al. | Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma | |
| JP2017501129A5 (enExample) | ||
| JP2017509342A5 (enExample) | ||
| JP2016196468A5 (enExample) | ||
| JP2017522903A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| RU2016124163A (ru) | Сконструированные высокоаффинные t-клеточные рецепторы человека | |
| US20240352136A1 (en) | Antibodies for the treatment of aml |